Discover 7 treatments for ischemic heart disease that are saving lives. From cutting-edge medications to advanced procedures changing cardiac care forever.

The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application (BLA) for sibeprenlimab for the treatment of immunoglobulin A nephropathy (IgAN) in adults.

Belgian company Augustine Therapeutics has initiated subject dosing in the randomised Phase I trial of AGT-100216, a ...

New drug lorundrostat shows promising results in lowering blood pressure for patients with resistant hypertension.

Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Oral 8-aminoguanine (8-AG) treatment preserved retinal structure and rod function in aged Fischer 344 rats, significantly ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced that ...

Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...